3,543 reports of this reaction
4.1% of all RIBOCICLIB reports
#2 most reported adverse reaction
NAUSEA is the #2 most commonly reported adverse reaction for RIBOCICLIB, manufactured by Novartis Pharmaceuticals Corporation. There are 3,543 FDA adverse event reports linking RIBOCICLIB to NAUSEA. This represents approximately 4.1% of all 86,238 adverse event reports for this drug.
RIBOCICLIB has an overall safety score of 85 out of 100. Patients taking RIBOCICLIB who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among RIBOCICLIB users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for RIBOCICLIB:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 3,543 FDA reports for RIBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 4.1% of all adverse event reports for RIBOCICLIB, making it one of the most commonly reported side effect.
If you experience nausea while taking RIBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.